Article Information
History
- January 15, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Sara Fañanas-Baquero1,2,#,
- Oscar Quintana-Bustamante1,2,#,
- Daniel P. Dever3,
- Omaira Alberquilla1,2,
- Rebeca Sanchez1,2,
- Joab Camarena3,
- Isabel Ojeda-Perez1,2,
- Mercedes Dessy-Rodriguez1,2,
- Rolf Turk4,
- Mollie S. Schubert4,
- Jose L. Lopez-Lorenzo5,
- Paola Bianchi6,
- Juan A. Bueren1,2,
- Mark A. Behlke4,
- Matthew Porteus3 and
- Jose-Carlos Segovia1,2,*
- 1Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- 2Unidad Mixta de Terapias Avanzadas. Instituto de Investigación Sanitaria Fundación Jiménez. (IIS-FJD, UAM). Madrid, Spain
- 3Department of Pediatrics, Stanford University, Stanford, California, USA
- 4Integrated DNA Technologies, Coralville, Iowa, USA
- 5Hospital Universitario Fundación Jiménez Díaz. Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM). Madrid, Spain
- 6UOC Ematologia, Fisiopatologia delle Anemie, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
- ↵*Corresponding author: Jose-Carlos Segovia, CIEMAT (Building 70). Av. Complutense, 40. 28040 Madrid. Spain, Tfn: +34913466268, Fax: +34913466484, E-mail: jc.segovia{at}ciemat.es